GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
enzastaurin Sensitive: D – Preclinical
|
enzastaurin Sensitive: D – Preclinical
|
GNAQ Q209P
|
Melanoma
|
GNAQ Q209P
|
Melanoma
|
PLX4720 Resistant: D – Preclinical
|
PLX4720 Resistant: D – Preclinical
|
GNAQ Q209P
|
Melanoma
|
GNAQ Q209P
|
Melanoma
|
CI-1040 Resistant: D – Preclinical
|
CI-1040 Resistant: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
selumetinib + AZD8055 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
REC-4881 Sensitive: D – Preclinical
|
REC-4881 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
trametinib + GSK2126458 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
AEB071 Sensitive: D – Preclinical
|
AEB071 Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
GNAQ Q209P
|
Uveal Melanoma
|
GNAQ Q209P
|
Uveal Melanoma
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|
trametinib + hydroxychloroquine Sensitive: D – Preclinical
|